Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.
fatty liver disease
gallstones
metabolism dysfunction
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
revised:
10
11
2023
received:
26
09
2023
accepted:
20
12
2023
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
11
1
2024
Statut:
aheadofprint
Résumé
The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged ≥ 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged ≥ 50 years is important for gallstone prevention.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women.
METHODS
METHODS
This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage.
RESULTS
RESULTS
After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged ≥ 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women.
CONCLUSION
CONCLUSIONS
Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged ≥ 50 years is important for gallstone prevention.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012; 6: 172-187. https://doi.org/10.5009/gnl.2012.6.2.172
Shabanzadeh DM, Holmboe SA, Sørensen LT, Linneberg A, Andersson AM, Jørgensen T. Are incident gallstones associated to sex-dependent changes with age? A cohort study. Andrology 2017; 5: 931-938. https://doi.org/10.1111/andr.12391
Granel-Villach L, Gil-Fortuño M, Fortea-Sanchis C, Gamón-Giner RL, Martínez-Ramos D, Escrig-Sos VJ. Factors that influence bile fluid microbiology in cholecystectomized patients. Rev. Gastroenterol. Mex. (Engl Ed) 2020; 85: 257-263. https://doi.org/10.1016/j.rgmxen.2019.05.008
Nardone G, Ferber IA, Miller LJ. The integrity of the cholecystokinin receptor gene in gallbladder disease and obesity. Hepatology 1995; 22: 1751-1753. https://doi.org/10.1002/hep.1840220621
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357. https://doi.org/10.1002/hep.29367
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84. https://doi.org/10.1002/hep.28431
Yasui K, Hashimoto E, Komorizono Y et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2011; 9: 428-433. https://doi.org/10.1016/j.cgh.2011.01.023
Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open 2020; 10: e036663. https://doi.org/10.1136/bmjopen-2019-036663
Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol. Clin. North Am. 1991; 20: 1-9. https://doi.org/10.1016/S0889-8553(21)00531-8
Tsunoda K, Shirai Y, Hatakeyama K. Prevalence of cholesterol gallstones positively correlates with per capita daily calorie intake. Hepatogastroenterology 2004; 51: 1271-1274.
Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 2012; 47: 586-595. https://doi.org/10.1007/s00535-012-0533-z
Jarvis H, Craig D, Barker R et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020; 17: e1003100. https://doi.org/10.1371/journal.pmed.1003100
Konyn P, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A, Kim D. Gallstone disease and its association with nonalcoholic fatty liver disease, all-cause and cause-specific mortality. Clin. Gastroenterol. Hepatol. 2023; 21: 940-948.e2. https://doi.org/10.1016/j.cgh.2022.04.043
Kichloo A, Solanki S, Haq KF et al. Association of non-alcoholic fatty liver disease with gallstone disease in the United States hospitalized patient population. World J. Gastrointest. Pathophysiol. 2021; 12: 14-24. https://doi.org/10.4291/wjgp.v12.i2.14
Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312
Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 2020; 73: 202-209. https://doi.org/10.1016/j.jhep.2020.03.039
Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front. Med. (Lausanne) 2021; 8: 693507. https://doi.org/10.3389/fmed.2021.693507
van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study. Hepatology 2022; 75: 419-429. https://doi.org/10.1002/hep.32131
Tsutsumi T, Eslam M, Kawaguchi T et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol. Res. 2021; 51: 1115-1128. https://doi.org/10.1111/hepr.13685
Yamamura S, Eslam M, Kawaguchi T et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020; 40: 3018-3030. https://doi.org/10.1111/liv.14675
Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J. Hepatol. 2021; 75: 1284-1291. https://doi.org/10.1016/j.jhep.2021.07.035
Sun DQ, Jin Y, Wang TY et al. MAFLD and risk of CKD. Metabolism 2021; 115: 154433. https://doi.org/10.1016/j.metabol.2020.154433
Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023: 101133. https://doi.org/10.1016/j.jhep.2023.06.003
Yilmaz Y. The heated debate over NAFLD renaming: an ongoing saga. Hepatol. Forum 2023; 4: 89-91. https://doi.org/10.14744/hf.2023.2023.0044
Third National Health and Nutrition Examination Survey: Gallbladder Ultrasonography Procedure Manual. Centers for Disease Control and Prevention (CDC)/National Center for Health Statistics (NCHS). 1988. Accessed April 14, 2023. Available from URL: https://wwwn.cdc.gov/nchs/data/nhanes3/manuals/gallblad.pdf
Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750. https://doi.org/10.1053/gast.2002.35354
Albert PS, Follmann DA, Barnhart HX. A generalized estimating equation approach for modeling random length binary vector data. Biometrics 1997; 53: 1116-1124. https://doi.org/10.2307/2533568
Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin. Emerg. Drugs 2006; 11: 429-444. https://doi.org/10.1517/14728214.11.3.429
Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract. Res. Clin. Gastroenterol. 2006; 20: 981-996. https://doi.org/10.1016/j.bpg.2006.05.004
Liew PL, Lee WJ, Wang W et al. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes. Surg. 2008; 18: 847-853. https://doi.org/10.1007/s11695-007-9355-0
de Bari O, Wang TY, Liu M, Portincasa P, Wang DQ. Estrogen induces two distinct cholesterol crystallization pathways by activating ERα and GPR30 in female mice. J. Lipid Res. 2015; 56: 1691-1700. https://doi.org/10.1194/jlr.M059121
Aune D, Vatten LJ. Diabetes mellitus and the risk of gallbladder disease: a systematic review and meta-analysis of prospective studies. J. Diabetes Complications 2016; 30: 368-373. https://doi.org/10.1016/j.jdiacomp.2015.11.012
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Macronutrients and insulin resistance in cholesterol gallstone disease. Am. J. Gastroenterol. 2008; 103: 2932-2939. https://doi.org/10.1111/j.1572-0241.2008.02189.x
Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009; 48: 1-26. https://doi.org/10.1016/j.plipres.2008.08.001
Banim PJ, Luben RN, Bulluck H, Sharp SJ, Wareham NJ, Khaw KT, Hart AR. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk). Eur. J. Gastroenterol. Hepatol. 2011; 23: 733-740. https://doi.org/10.1097/MEG.0b013e3283477cc9
Asai Y, Yamada T, Tsukita S et al. Activation of the hypoxia inducible factor 1α subunit pathway in steatotic liver contributes to formation of cholesterol gallstones. Gastroenterology 2017; 152: 1521-1535.e8. https://doi.org/10.1053/j.gastro.2017.01.001
Wang TY, Portincasa P, Liu M, Tso P, Wang DQ. Mouse models of gallstone disease. Curr. Opin. Gastroenterol. 2018; 34: 59-70. https://doi.org/10.1097/MOG.0000000000000417
Fairfield CJ, Drake TM, Pius R et al. Genome-wide analysis identifies gallstone-susceptibility loci including genes regulating gastrointestinal motility. Hepatology 2022; 75: 1081-1094. https://doi.org/10.1002/hep.32199
Aune D, Vatten LJ, Boffetta P. Tobacco smoking and the risk of gallbladder disease. Eur. J. Epidemiol. 2016; 31: 643-653. https://doi.org/10.1007/s10654-016-0124-z
Wirth J, Joshi AD, Song M et al. A healthy lifestyle pattern and the risk of symptomatic gallstone disease: results from 2 prospective cohort studies. Am. J. Clin. Nutr. 2020; 112: 586-594. https://doi.org/10.1093/ajcn/nqaa154
Weerakoon HT, Ranasinghe JG, Navaratna A, Sivakanesan R, Galketiya KB, Rosairo S. Can the type of gallstones be predicted with known possible risk factors?: a comparison between mixed cholesterol and black pigment stones. BMC Gastroenterol. 2014; 14: 88-96. https://doi.org/10.1186/1471-230X-14-88
Portincasa P, Moschetta A, Berardino M et al. Impaired gallbladder motility and delayed orocecal transit contribute to pigment gallstone and biliary sludge formation in beta-thalassemia major adults. World J. Gastroenterol. 2004; 10: 2383-2390. https://doi.org/10.3748/wjg.v10.i16.2383